DBV Technologies S.A. (NASDAQ:DBVT – Get Rating) has earned an average rating of “Hold” from the seven analysts that are presently covering the stock, MarketBeat.com reports. Four analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $4.50.
A number of equities research analysts have recently commented on the company. Zacks Investment Research upgraded DBV Technologies from a “hold” rating to a “buy” rating and set a $1.50 target price on the stock in a research note on Thursday, May 5th. HC Wainwright reiterated a “buy” rating and set a $10.00 target price on shares of DBV Technologies in a research note on Tuesday, May 3rd. The Goldman Sachs Group cut DBV Technologies from a “buy” rating to a “neutral” rating and lowered their target price for the stock from $6.00 to $1.50 in a research note on Monday, May 9th. Finally, StockNews.com initiated coverage on DBV Technologies in a research note on Friday, May 13th. They set a “hold” rating on the stock.
Institutional investors and hedge funds have recently made changes to their positions in the stock. FNY Investment Advisers LLC purchased a new position in DBV Technologies during the 4th quarter valued at about $32,000. PNC Financial Services Group Inc. purchased a new position in DBV Technologies during the 3rd quarter valued at about $36,000. Envestnet Asset Management Inc. purchased a new position in DBV Technologies during the 4th quarter valued at about $43,000. Virtu Financial LLC purchased a new position in DBV Technologies during the 4th quarter valued at about $85,000. Finally, BlackRock Inc. grew its holdings in DBV Technologies by 60.5% during the 3rd quarter. BlackRock Inc. now owns 22,350 shares of the company’s stock valued at $110,000 after buying an additional 8,422 shares in the last quarter. 19.33% of the stock is owned by institutional investors.
DBV Technologies (NASDAQ:DBVT – Get Rating) last released its earnings results on Thursday, March 3rd. The company reported ($0.13) EPS for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.19. The business had revenue of $2.93 million for the quarter, compared to the consensus estimate of $3.97 million. On average, analysts forecast that DBV Technologies will post -0.69 earnings per share for the current fiscal year.
About DBV Technologies (Get Rating)
DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults.
- Get a free copy of the StockNews.com research report on DBV Technologies (DBVT)
- 3 Retailers That Defied First Quarter Headwinds
- Will John Deere’s Earnings Help to Calm the Markets?
- Rapid7: Could Be Profitable in FY 2022 Despite Bear Market
- Lowe’s Companies Has Not Bottomed
- Silicon Labs Stock is Falling to a Better Place
Receive News & Ratings for DBV Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies and related companies with MarketBeat.com's FREE daily email newsletter.